Gilead Says Spinoff Of HCV Business Is “Not High On List Of Priorities”

There was much investor chatter last month that Gilead Sciences(GILD) could unlock value by splitting its Hepatitis C business from its HIV business.  RBC Capital advanced the case in a note RBC Capital suggested the drugmaker would be better off cutting its businesses right down the middle, saying that shares could jump by as much as 40% if… Read More »